Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy Patients

Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy Patients

Background. The peritoneal surface is an acknowledged locoregional failure site of abdominal malignancies. Previous treatment attempts with medical therapy alone did not result in long-term survival. During the last two decades, new treatment protocols combining cytoreductive surgery with perioperat...

Full description

Bibliographic Details
Main Authors: K. Van der Speeten, K. Govaerts, O. A. Stuart, P. H. Sugarbaker
Format: Article
Language:English
Published: Hindawi Limited 2012-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2012/378064
id doaj-f13d541f9177426fa1136498c5c2e121
record_format Article
spelling doaj-f13d541f9177426fa1136498c5c2e1212020-11-24T21:59:50ZengHindawi LimitedGastroenterology Research and Practice1687-61211687-630X2012-01-01201210.1155/2012/378064378064Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy PatientsK. Van der Speeten0K. Govaerts1O. A. Stuart2P. H. Sugarbaker3Department of Surgical Oncology, Oost-Limburg Hospital, Schiepse Bos 6, 3600 Genk, BelgiumDepartment of Surgical Oncology, Oost-Limburg Hospital, Schiepse Bos 6, 3600 Genk, BelgiumWashington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USAWashington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USABackground. The peritoneal surface is an acknowledged locoregional failure site of abdominal malignancies. Previous treatment attempts with medical therapy alone did not result in long-term survival. During the last two decades, new treatment protocols combining cytoreductive surgery with perioperative intraperitoneal and intravenous cancer chemotherapy have demonstrated very encouraging clinical results. This paper aims to clarify the pharmacologic base underlying these treatment regimens. Materials and Methods. A review of the current pharmacologic data regarding these perioperative chemotherapy protocols was undertaken. Conclusions. There is a clear pharmacokinetic and pharmacodynamic rationale for perioperative intraperitoneal and intravenous cancer chemotherapy in peritoneal surface malignancy patients.http://dx.doi.org/10.1155/2012/378064
collection DOAJ
language English
format Article
sources DOAJ
author K. Van der Speeten
K. Govaerts
O. A. Stuart
P. H. Sugarbaker
spellingShingle K. Van der Speeten
K. Govaerts
O. A. Stuart
P. H. Sugarbaker
Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy Patients
Gastroenterology Research and Practice
author_facet K. Van der Speeten
K. Govaerts
O. A. Stuart
P. H. Sugarbaker
author_sort K. Van der Speeten
title Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy Patients
title_short Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy Patients
title_full Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy Patients
title_fullStr Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy Patients
title_full_unstemmed Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy Patients
title_sort pharmacokinetics of the perioperative use of cancer chemotherapy in peritoneal surface malignancy patients
publisher Hindawi Limited
series Gastroenterology Research and Practice
issn 1687-6121
1687-630X
publishDate 2012-01-01
description Background. The peritoneal surface is an acknowledged locoregional failure site of abdominal malignancies. Previous treatment attempts with medical therapy alone did not result in long-term survival. During the last two decades, new treatment protocols combining cytoreductive surgery with perioperative intraperitoneal and intravenous cancer chemotherapy have demonstrated very encouraging clinical results. This paper aims to clarify the pharmacologic base underlying these treatment regimens. Materials and Methods. A review of the current pharmacologic data regarding these perioperative chemotherapy protocols was undertaken. Conclusions. There is a clear pharmacokinetic and pharmacodynamic rationale for perioperative intraperitoneal and intravenous cancer chemotherapy in peritoneal surface malignancy patients.
url http://dx.doi.org/10.1155/2012/378064
work_keys_str_mv AT kvanderspeeten pharmacokineticsoftheperioperativeuseofcancerchemotherapyinperitonealsurfacemalignancypatients
AT kgovaerts pharmacokineticsoftheperioperativeuseofcancerchemotherapyinperitonealsurfacemalignancypatients
AT oastuart pharmacokineticsoftheperioperativeuseofcancerchemotherapyinperitonealsurfacemalignancypatients
AT phsugarbaker pharmacokineticsoftheperioperativeuseofcancerchemotherapyinperitonealsurfacemalignancypatients
_version_ 1725846984879767552

Similar Items